TVTX - Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress | Benzinga
Presentations highlight data supporting FILSPARI® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients with IgAN
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the National Kidney Foundation (NKF) Spring Clinical Meetings in Long Beach, California, May 14-18, 2024, and the European Renal Association (ERA) Congress in Stockholm, May 23-26, 2024.
At NKF the Company will present analyses comparing the effect of FILSPARI (sparsentan) as seen in the Phase 3 PROTECT Study in slowing kidney function decline versus RAS inhibition in real-world use and in clinical trials in patients with IgA nephropathy (IgAN). Additionally, new 48-week findings from the SPARTAN Study evaluating FILSPARI as a first-line treatment for patients with IgAN will be presented as a top-rated NKF abstract. At ERA the company will present a matching-adjusted indirect comparison of two-year efficacy outcomes between FILSPARI from the Phase 3 PROTECT Study and targeted-release formulation budesonide plus RAS inhibition from the NefIgArd trial.
"At the NKF and ERA meetings we're pleased to present critical analyses which demonstrate FILSPARI's superior efficacy over historic RASi standard of care," said Jula Inrig, M.D., chief medical officer of Travere Therapeutics. "We continue to see that a non-immunosuppressive therapy that targets injury directly in the kidney can reshape optimal foundational patient care in IgAN."
NKF Oral Presentation
Matching-Adjusted Indirect Comparisons of eGFR Slopes in the PROTECT Study with UK RaDaR IgA Nephropathy Population and the Control Arm of NefIgArd Poster 446
Session: Late-breaking oral presentation and continuing medical education: May 15, 2:30-3:00 p.m. PT
Poster: May 15, 2024, 5:30-7:00 p.m. PT
NKF Poster Presentations
Sparsentan (SPAR) Shows Clinically Meaningful Treatment Effects vs Irbesartan (IRB) in Patients With IgA Nephropathy (IgAN) in the Phase 3 PROTECT Trial
Poster: 375
Session: Glomerular diseases
May 15, 2024, 5:30-7:00 p.m. PT
Sparsentan as First-line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial*
Poster: 384
Session: Glomerular diseases
May 15, 2024, 5:30-7:00 p.m. PT
*Designated a top-rated abstract by NKF
Sparsentan vs Irbesartan in Patients With Focal Segmental Glomerulosclerosis (FSGS): Results From the DUPLEX Trial
Poster: 406
Session: Glomerular diseases
May 15, 2024, 5:30-7:00 p.m. PT
ERA Oral Presentations
PROTECT and NefIgArd Two-Year Proteinuria and eGFR Outcomes in Adults with IgA Nephropathy: Matching-Adjusted Indirect Comparison
Topic: Glomerular & tubulo-interstitial diseases
Subtopic: B4 – Prevention, treatment & clinical trials
Focused Oral Room 2; May 25, 2024, 12:40-12:45 p.m. CET
Matching-Adjusted Indirect Comparisons of eGFR slopes in the PROTECT Study with UK RaDaR IgA Nephropathy Population and the Control Arm of NefIgArd
Topic: Glomerular & tubulo-interstitial diseases
Subtopic: B4 – Prevention, treatment & clinical trials
Focused Oral Room 2; May 25, 2024, 3:15-3:20 p.m. CET
Natural History of Idiopathic Nephrotic Syndrome: The UK National RaDaR Idiopathic Nephrotic Syndrome Cohort
Topic: Chronic kidney disease
Session: Moderated oral 1.3
Room T6; May 24, 2024, 8:39-8:48 a.m. CET
Sparsentan has Direct Effects on the Glomerular Capillary Wall to Attenuate Increased Permeability after Exposure to Nephrotic Syndrome Plasma
Topic: Glomerular & tubulo-interstitial diseases
Subtopic: B1- Basic science, experimental & renal pathology
Session: FC17+ML Antigen-specific immune cell depletion for autoimmune diseases
Free communication; Room A5; May 25, 2024, 4:00-4:12 p.m. CET
ERA Poster Presentation
Humanistic Burden of Immunoglobulin A Nephropathy and Focal Segmental Glomerulosclerosis on Patients and Care-Partners (HONUS): Results for Europe ?
?Topic: Glomerular & tubulo-interstitial diseases
Subtopic: B4 – Prevention, treatment & clinical trials
ePoster; Available online on the virtual platform for participants during the congress
About IgA Nephropathy
IgA nephropathy (IgAN), also called Berger's disease, is a rare progressive kidney disease characterized by the buildup of immunoglobulin A (IgA), a protein that helps the body fight infections, in the kidneys. The deposits of IgA cause a breakdown of the normal filtering mechanisms in the kidney, leading to blood in the urine (hematuria), protein in the urine (proteinuria) and a progressive loss of kidney function. Other symptoms of IgAN may include swelling (edema) and high blood pressure.
IgAN is the most common type of primary glomerulonephritis worldwide and a leading cause of kidney failure due to glomerular disease. IgAN is estimated to affect up to 150,000 people in the U.S. and is one of the most common glomerular diseases in Europe and Japan.
About Focal Segmental Glomerulosclerosis
Focal segmental glomerulosclerosis (FSGS) is a rare proteinuric kidney disorder in both children and adults that is estimated to affect more than 40,000 patients in the U.S. with similar prevalence in Europe. The disorder is defined by progressive scarring of the kidney and often leads to kidney failure. FSGS is characterized by proteinuria, where protein leaks into the urine due to a breakdown of the normal filtration mechanism in the kidney. Once in the urine, protein is considered to be toxic to other parts of the kidney, especially the tubules, and is believed to contribute to further disease progression. Other common symptoms include swelling in parts ...